What are the new guidelines for A1C?
ADA now recommends A1C below 7% or TIR above 70%, and time below range lower than 4% for most adults. In previous years, the Standards of Care included an “A1C Testing” subsection that recommended people with diabetes test their A1C two to four times a year with an A1C target below 7%.
Is an A1C of 5.6 good?
In general: An A1C level below 5.7% is considered normal. An A1C level between 5.7% and 6.4% is considered prediabetes. An A1C level of 6.5% or higher on two separate tests indicates type 2 diabetes.
What is the ADA’s goal for fasting blood sugar?
In terms of fasting glucose, recommended goals are set within a 70–130 mg/dl (3.9–7.2 mmol/l) range for the American Diabetes Association (17) and at <110 mg/dl (6.1 mmol/l) and 100 mg/dl (5.5 mmol/l) for the American College of Endocrinologists (18) and the International Diabetes Federation (19), respectively.
Is a 6.0 A1C OK?
For most people with diabetes, the general A1C goal is to have a level between 6.0 and 6.9. While it might sound like the ideal A1C target is under 6.0, for those with diabetes, this level can indicate low blood sugar levels, which can be just as dangerous as high blood sugar levels.
Do I need medication if my A1C is 7?
It is now recommended that people with type 2 diabetes should be treated to hit an A1C level between 7 and 8 percent instead of the previous 6.5 to 7 percent benchmark, but these new guidelines have drawn controversy.
What is the danger zone for A1C?
3 An A1C level above 7% means someone is at an increased risk of complications from diabetes, which should prompt a person to make sure they have a plan in place to manage their blood sugar levels and decrease this risk.
What is the A1C goal for diabetes in primary prevention of stroke?
Glycemic targets should be individualized to achieve: In general, A1c values should be targeted to ≤7.0% in patients with either type 1 or type 2 diabetes (and stroke or transient ischemic attack), as this target provides strong benefits for the prevention of microvascular complications [Evidence Level A].